Coastlands Capital LP
Coastlands Capital LP's purchase track record
Coastlands Capital LP has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/9/2026 | ADIL | $41K | +41.8% | pending | — |
| 6/29/2026 | ADIL | $65K | +56.0% | pending | — |
| 6/17/2026 | KTTA | $53K | -2.4% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Eloxx Pharmaceuticals Included in Pre-Market Movers List. Eloxx Pharmaceuticals was featured in a recent roundup of healthcare stocks showing movement during Monday's pre-market session. The company currently trades with a low trailing P/E ratio of 5.3, which is significantly below the average analyst target price of $38.25. This inclusion highlights current market attention on the stock, though the specific drivers for the pre-market activity are not detailed in the provided report.
Transaction History
| ADIL | ▲ Buy | Open Market | 1,233 | $3K | 7/16/2026 | View on chart |
| ADIL | ▲ Buy | Open Market | 2,000 | $5K | 7/14/2026 | View on chart |
| ADIL | ▲ Buy | Open Market | 1,700 | $5K | 7/10/2026 | View on chart |
| ADIL | ▲ Buy | Open Market | 10,053 | $28K | 7/9/2026 | View on chart |
| ADIL | ▲ Buy | Open Market | 25,000 | $65K | 6/29/2026 | View on chart |
| KTTA | ▲ Buy | Open Market | 100,000 | $53K | 6/17/2026 | View on chart |
| ELOX | ▼ Sell | Other | 1,250,000 | $0 | 5/27/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Adial Pharmaceuticals Announces Nasdaq Inducement Grant
Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.
Adial Pharmaceuticals Announces Nasdaq Inducement Grant. Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.